全文获取类型
收费全文 | 33477篇 |
免费 | 3436篇 |
国内免费 | 2301篇 |
专业分类
耳鼻咽喉 | 277篇 |
儿科学 | 494篇 |
妇产科学 | 388篇 |
基础医学 | 3654篇 |
口腔科学 | 716篇 |
临床医学 | 4331篇 |
内科学 | 4873篇 |
皮肤病学 | 320篇 |
神经病学 | 1309篇 |
特种医学 | 1138篇 |
外国民族医学 | 15篇 |
外科学 | 3573篇 |
综合类 | 6036篇 |
现状与发展 | 7篇 |
一般理论 | 2篇 |
预防医学 | 2328篇 |
眼科学 | 989篇 |
药学 | 3895篇 |
22篇 | |
中国医学 | 2091篇 |
肿瘤学 | 2756篇 |
出版年
2024年 | 59篇 |
2023年 | 551篇 |
2022年 | 907篇 |
2021年 | 1691篇 |
2020年 | 1467篇 |
2019年 | 1184篇 |
2018年 | 1247篇 |
2017年 | 1211篇 |
2016年 | 1098篇 |
2015年 | 1682篇 |
2014年 | 2100篇 |
2013年 | 1958篇 |
2012年 | 2745篇 |
2011年 | 2882篇 |
2010年 | 1988篇 |
2009年 | 1606篇 |
2008年 | 1950篇 |
2007年 | 1833篇 |
2006年 | 1759篇 |
2005年 | 1411篇 |
2004年 | 1108篇 |
2003年 | 943篇 |
2002年 | 818篇 |
2001年 | 667篇 |
2000年 | 645篇 |
1999年 | 637篇 |
1998年 | 414篇 |
1997年 | 397篇 |
1996年 | 345篇 |
1995年 | 333篇 |
1994年 | 301篇 |
1993年 | 173篇 |
1992年 | 210篇 |
1991年 | 162篇 |
1990年 | 123篇 |
1989年 | 109篇 |
1988年 | 116篇 |
1987年 | 112篇 |
1986年 | 93篇 |
1985年 | 70篇 |
1984年 | 28篇 |
1983年 | 25篇 |
1982年 | 12篇 |
1981年 | 16篇 |
1980年 | 6篇 |
1979年 | 11篇 |
1976年 | 2篇 |
1963年 | 1篇 |
1962年 | 1篇 |
1961年 | 1篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
11.
Bingqi Ma Huijuan Meng Ye Tian Yingying Wang Tianqiang Song Ti Zhang Qiang Wu Yunlong Cui Huikai Li Wei Zhang Qiang Li 《Oncology Letters》2021,21(1)
Herpesvirus entry mediator (HVEM) displays dual signals in T-cell activation according to the ligands and intracytoplasmic effectors it interacts with. High HVEM expression may play an immunosuppressive role in several malignancies. The present study investigated the clinical impact of HVEM on intrahepatic cholangiocarcinoma (ICC), including its prognostic value, and association with clinicopathological features and immune status. The clinical data of 102 consecutive patients with ICC who underwent surgical treatment from January 2012 to December 2017 were collected. The expression of HVEM and different types of tumor-infiltrating lymphocytes (TILs) were investigated in ICC tissue samples by immunohistochemical staining. HVEM expression was detected in the tumor tissues of 92 (90.2%) patients with ICC. Patients with high HVEM expression were more likely to have increased peripheral blood lymphocyte (PBL) concentrations (P=0.031), decreased CEA (P=0.036), low TNM stage (P=0.043) and high frequencies of small-duct histological type (P=0.021) and BAP1 retained expression (P=0.010). Survival analysis showed that high HVEM expression was a favorable independent predictor of overall postoperative survival (P=0.034, hazard ratio=0.486, 95% confidence interval=0.249–0.945). In addition, no significant association of HVEM expression with CD4+ (P=0.512), CD8+ (P=0.750) or CD45RO+ (P=0.078) TILs was identified in the ICC tissues. These results indicate that HVEM may serve as a favorable prognostic marker for ICC. Furthermore, co-stimulatory signals from HVEM may play a dominant role in the progression of ICCs, which can be explained by an increase in the number of PBLs rather than a change in the number of TILs. However, the function of the HVEM network in ICC progression is complex and requires further study. 相似文献
12.
To investigate the feasibility of arterial spin labeling (ASL) blood flow (BF) and its histogram analysis to distinguish early-stage nasopharyngeal carcinoma (NPC) from nasopharyngeal lymphoid hyperplasia (NPLH).Sixty-three stage T1 NPC patients and benign NPLH patients underwent ASL on a 3.0-T magnetic resonance imaging system. BF histogram parameters were derived automatically, including the mean, median, maximum, minimum, kurtosis, skewness, and variance. Absolute values were obtained for skewness and kurtosis (absolute value of skewness [AVS] and absolute value of kurtosis [AVK], respectively). The Mann–Whitney U test, receiver operating characteristic curve, and multiple logistic regression models were used for statistical analysis.The mean, maximum, and variance of ASL BF values were significantly higher in early-stage NPC than in NPLH (all P < 0.0001), while the median and AVK values of early-stage NPC were also significantly higher than those of NPLH (all P < 0.001). No significant difference was found between the minimum and AVS values in early-stage NPC compared with NPLH (P = 0.125 and P = 0.084, respectively). The area under the curve (AUC) of the maximum was significantly higher than those of the mean and median (P < 0.05). The AUC of variance was significantly higher than those of the other parameters (all P < 0.05). Multivariate analysis showed that variance was the only independent predictor of outcome (P < 0.05).ASL BF and its histogram analysis could distinguish early-stage NPC from NPLH, and the variance value was a unique independent predictor. 相似文献
13.
Background:The progress of modern society and changes in lifestyle have not only increased the proportion of sub-healthy people, but also caused many people to suffer from sleep disorders and mental anxiety. Long-term lack of high-quality sleep will not only cause psychological problems such as anxiety and fatigue, but also cause physical abnormalities, such as abnormal hormone secretion, weakened immunity, neuroendocrine disorders, and high blood pressure. Therefore, the purpose of this study is to systematically evaluate the effectiveness of aromatherapy in improving sleep quality in people with sleep disorders.Methods:Computer search CNKI, SinoMed, Wanfang, PubMed, Web of science, and EMbase collect randomized controlled trials on aromatherapy to improve sleep quality of people with sleep disorders. The search time limit is to build the database until April 5, 2021. RevMan5.3 software is used for meta-analysis.Results:This systematic review will provide an assessment of the current state of sleep disorders, aiming to assess the efficacy of aromatherapy for patients with sleep disorders.Conclusion:This systematic review will provide a credible evidence-based for the clinical treatment of sleep disorders with aromatherapy. 相似文献
14.
Yan Gao MD Yizhen Liu MD PhD Yafei Wang MD Qingyuan Zhang MD Depei Wu MD Xu Ye MD Jianqiu Wu MD Wei Xu MD Jianfeng Zhou MD Yu Yang MD Hong Cen MD Feng Zhang MD Ying Xiang MD Xiaoqiong Tang MD Kaiyang Ding MD JinYing Lin MD Lei Ma MD Shunqing Wang MD Hao Yu MD Yang Zhao MD Bin Song MD Fangfang Lv MD Huiqiang Huang MD 《Cancer》2023,129(4):551-559
15.
Ye Young Shin Yoojin Seo Su-Jeong Oh Ji-Su Ahn Min-hye Song Min-Jung Kang Jung-Min Oh Dongjun Lee Yun Hak Kim Eui-Suk Sung Hyung-Sik Kim 《Journal of pineal research》2022,72(1):e12779
The prevalence of head and neck squamous cell carcinoma (HNSCC) has continued to rise for decades. However, drug resistance to chemotherapeutics and relapse, mediated by cancer stem cells (CSCs), remains a significant impediment in clinical oncology to achieve successful treatment. Therefore, we focused on analyzing CSCs in HNSCC and demonstrated the effect of melatonin (Mel) and verteporfin (VP) on SCC-25 cells. HNSCC CSCs were enriched in the reactive oxygen species-low state and in sphere-forming cultures. Combination treatment with Mel and VP decreased HNSCC viability and increased apoptosis without causing significant damage to normal cells. Sphere-forming ability and stem cell population were reduced by co-treatment with Mel and VP, while mitochondrial ROS level was increased by the treatment. Furthermore, the expression of mitophagy markers, parkin and PINK1, was significantly decreased in the co-treated cells. Mel and VP induced mitochondrial depolarization and inhibited mitochondrial function. Parkin/TOM20 was localized near the nucleus and formed clusters of mitochondria in the cells after treatment. Moreover, Mel and VP downregulated the expression of markers involved in epithelial-mesenchymal transition and metastasis. The migration capacity of cells was significantly decreased by co-treatment with Mel and VP, accompanied by the down-regulation of MMP-2 and MMP-9 expression. Taken together, these results indicate that co-treatment with Mel and VP induces mitochondrial dysfunction, resulting in the apoptosis of CSCs. Mel and VP could thus be further investigated as potential therapies for HNSCC through their action on CSCs. 相似文献
16.
目的:探讨单孔胸腔镜下肺癌手术术后胸腔引流时间的影响因素。方法:本研究采用回顾性分析方法,回顾我院2018年01月至2019年12月原发性肺癌患者经单孔胸腔镜手术治疗的病例199例。按照术后胸腔引流时间分为两组,Ⅰ组(术后胸腔引流时间<5天)和Ⅱ组(术后胸腔引流时间≥5天)。对于影响术后胸腔引流时间的可能因素在两组间先采用单因素分析的方法筛选,再将筛选出来的对术后胸腔引流时间可能有意义的影响因素进行二项Logistic多因素回归分析。结果:经单因素分析及二项Logistic多因素回归分析结果显示:年龄≥60岁、手术部位、肺段切除术、胸膜粘连、手术时间≥180 min、术后早期下床活动是术后胸腔引流时间的独立影响因素(P<0.05)。结论:对于具有多个延长术后胸腔引流时间的独立影响因素的患者,应制定个体化管理方案,尽可能减少术后胸腔引流时间,减少住院天数,加快患者康复。 相似文献
17.
18.
19.
Qi Zhang Ye Zhou Lijie Song Weijia Fang Meng Qiu Yanhong Gu Yang Yang Jingdong Zhang Jing Liu Jian Li Ming Lu Tianxiao Gong Xin Wang Yan Li Jun Yang Yingjiang Ye Lin Shen 《International journal of cancer. Journal international du cancer》2023,153(11):1885-1893
Formal multidisciplinary team (MDT) discussions in clinical practice require time and space but have unclear survival benefits for advanced gastrointestinal cancer patients. Our study aimed to investigate the long-term survival of patients with advanced gastrointestinal cancer after MDT decision. From June 2017 to June 2019, continuous MDT discussions on advanced gastrointestinal cancer were conducted in 13 medical centers in China. MDT decisions and actual treatment received by patients were prospectively recorded. The primary endpoint was the difference in overall survival (OS) between patients in the MDT decision implementation and nonimplementation groups. The secondary endpoints included the implementation rate of MDT decisions and subgroup survival analysis. A total of 461 MDT decisions of 455 patients were included in our study. The implementation rate of MDT decisions was 85.7%. Previous treatment had an impact on MDT decision-making. The OS was 24.0 months and 17.0 months in the implementation and nonimplementation groups, respectively. The implementation of MDT decisions significantly reduced the risk of death in multivariate analyses (hazard ratio = 0.518; 95% confidence interval: 0.304-0.884, P = .016). Subgroup analysis showed a significant difference in survival of patients with colorectal cancer, but not in survival of patients with gastric cancer. The rate of secondary MDT discussion was only 5.6% among patients who the MDT decisions were discontinued due to changes in their condition. MDT discussion can prolong the OS of patients with advanced gastrointestinal cancer, especially those with colorectal cancer. Timely scheduling of the subsequent MDT discussion is necessary when the disease condition changes. 相似文献
20.
Tie Zhou Shengfei Qin Weidong Xu Shouyan Tang Guanghua Chen Song Li Jianguo Hou Xu Gao Guowei Shi Zhongquan Sun Jie Jin Lijun Chen Weibing Sun Ben Liu Jingen Wang Qinggui Meng Dongwen Wang Zhiquan Hu Dalin He Yong Yang Xishuang Song Cheng Fu Yinhuai Wang Dingwei Ye Wei Zhang 《International journal of cancer. Journal international du cancer》2023,153(4):792-802
We aim to assess the safety and efficacy of proxalutamide, a novel androgen receptor antagonist, for men with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter, randomized, open-label, phase 2 trial. In our study, the enrolled mCRPC patients were randomized to 100, 200 and 300 mg dose groups at 1:1:1. The primary efficacy endpoint was prostate-specific antigen (PSA) response rate. The secondary endpoints included objective response rate (ORR), disease control rate (DCR) and time to PSA and radiographic progression. Safety and pharmacokinetics were also assessed. Finally, there were 108 patients from 17 centers being enrolled. By week 16, there were 13 (35.1%), 12 (36.4%) and 15 (42.9%) patients with confirmed 50% or greater PSA decline in 100 mg (n = 37), 200 mg (n = 33) and 300 mg (n = 35) groups, respectively. Among the 19 patients with target lesions at study entry, three (15.8%) had a partial response and 12 (63.2%) had stable disease. The ORRs of 20.0%, 22.2%, 0% and DCRs of 80.0%, 88.9%, 60.0% were, respectively, achieved in 100, 200 and 300 mg groups. By the maximum follow-up time of 24 weeks, there were 42.6% and 10.2% of cases experiencing PSA progression and radiographic progression, respectively. Overall, adverse events (AEs) were experienced by 94.4% of patients, most of which were mild or moderate. There were 28 patients experiencing ≥grade 3 AEs. The most common AEs were fatigue (17.6%), anemia (14.8%), elevated AST (14.8%) and ALT (13.0%), decreased appetite (13.0%). These findings preliminarily showed the promising antitumor activity of proxalutamide in patients with mCRPC with a manageable safety profile. The proxalutamide dose of 200 mg daily is recommended for future phase 3 trial (Clinical trial registration no. CTR20170177). 相似文献